La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Gilead Sciences Croissance future

Future contrôle des critères 4/6

Gilead Sciences devrait augmenter ses bénéfices et son chiffre d'affaires de 36.3% et de 2.2% par an respectivement. Le BPA devrait croître de de 36.7% par an. Le rendement des capitaux propres devrait être 40.6% dans 3 ans.

Informations clés

35.9%

Taux de croissance des bénéfices

36.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.3%
Taux de croissance des recettes	2.2%
Rendement futur des capitaux propres	40.6%
Couverture par les analystes	Good
Dernière mise à jour	20 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13

Gilead Sciences: Cheap For A Reason

Feb 10

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:GILD - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	28,796	6,913	10,293	9,599	23
12/31/2025	27,987	6,582	10,139	9,711	27
12/31/2024	27,706	205	7,063	4,937	27
6/30/2024	27,805	1,054	6,896	7,468	N/A
3/31/2024	27,450	485	7,900	8,481	N/A
12/31/2023	27,116	5,665	7,421	8,006	N/A
9/30/2023	27,391	5,876	7,853	8,404	N/A
6/30/2023	27,382	5,484	8,926	9,512	N/A
3/31/2023	27,043	5,583	8,386	8,976	N/A
12/31/2022	27,281	4,592	8,344	9,072	N/A
9/30/2022	27,136	3,334	9,007	9,710	N/A
6/30/2022	27,515	4,137	9,415	10,100	N/A
3/31/2022	27,472	4,515	9,953	10,614	N/A
12/31/2021	27,305	6,225	10,805	11,384	N/A
9/30/2021	27,482	7,394	9,491	10,095	N/A
6/30/2021	26,638	5,162	8,472	9,092	N/A
3/31/2021	25,564	301	8,698	9,342	N/A
12/31/2020	24,689	123	7,518	8,168	N/A
9/30/2020	23,147	1,268	8,160	8,832	N/A
6/30/2020	22,174	-257	8,510	9,227	N/A
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	7,639	8,476	N/A
3/31/2019	22,320	5,892	6,758	7,707	N/A
12/31/2018	22,127	5,455	7,476	8,400	N/A
9/30/2018	22,281	1,587	7,912	8,808	N/A
6/30/2018	23,197	2,208	8,432	9,290	N/A
3/31/2018	24,690	3,464	N/A	11,243	N/A
12/31/2017	26,107	4,628	N/A	11,898	N/A
9/30/2017	27,478	11,601	N/A	12,684	N/A
6/30/2017	28,466	12,213	N/A	14,383	N/A
3/31/2017	29,101	12,637	N/A	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A
9/30/2014	20,696	9,406	N/A	10,524	N/A
6/30/2014	17,437	7,463	N/A	7,233	N/A
3/31/2014	13,669	4,580	N/A	4,001	N/A
12/31/2013	11,202	3,075	N/A	3,105	N/A
9/30/2013	10,585	3,046	N/A	3,084	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de GILD ( 36.3% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de GILD ( 36.3% par an) devraient croître plus rapidement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de GILD devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de GILD ( 2.2% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de GILD ( 2.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de GILD devrait être très élevé dans 3 ans ( 40.6 %).

Gilead Sciences Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 21%

Consensus EPS estimates fall by 79%

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Recent updates

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Consensus EPS estimates fall by 21%

Second quarter dividend of US$0.77 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

A Look At Gilead Sciences After Its Recent Weakness

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences: Cheap For A Reason

Fourth quarter dividend increased to US$0.77

Full year 2023 earnings: EPS misses analyst expectations